Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.70 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.68 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661898 | 0.93 | CYP4A11 (0.69) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL1629577 | 0.89 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL4199917 | 0.86 | CYP4A11 (0.70) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL13230897 | 0.84 | CYP4A11 (0.72) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL4128844 | 0.83 | CA12 (0.54) | CYP4A11CYP4F2HSD17B10ALDH1A1TP53 | |
| SCHEMBL70185 | 0.83 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL2654777 | 0.82 | CYP4A11 (1.00) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL1792416 | 0.82 | CYP4A11 (0.74) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL10609552 | 0.82 | CYP4A11 (0.74) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 | |
| SCHEMBL2263222 | 0.81 | CYP4A11 (0.71) | CYP4A11CYP4F2LOXL2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | CYP4A11 3481/4885CYP4F2 3252/4885LOXL2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.